Is RXRX or SANA more undervalued in 2026?

CirclFi compares Recursion Pharmaceuticals, Inc. (RXRX) and Sana Biotechnology, Inc. (SANA) using 13 institutional-grade valuation models. RXRX has a Quality of Company score of 6.5/10 while SANA scores 3.8/10.

Which is a better buy — RXRX or SANA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RXRX and SANA valuations compare?

RXRX at $3.44 and SANA at $3.13 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RXRX vs SANA Valuation Comparison 2026 — Intrinsic Value Analysis

RXRX

Biotechnology

Recursion Pharmaceuticals, Inc.

Quality

6.5

out of 10

Value Trap

LOW

Price

$3.44

Last close

Models

9/13

Active

SANA

Biotechnology

Sana Biotechnology, Inc.

Quality

3.8

out of 10

Value Trap

LOW

Price

$3.13

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	RXRX Fair Value	RXRX Upside	SANA Fair Value	SANA Upside
Bayesian DCF	Intrinsic	$1.52	-55.8%	$0.89	-71.4%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.04	-98.9%	$0.85	-72.9%
Dynamic NAV	Asset-Based	$1.99	-42.2%	$0.41	-86.8%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RXRX vs SANA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RXRX vs SANA — Which Stock Is More Undervalued?

RXRX scores higher with a 6.5/10 quality rating vs SANA's 3.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Recursion Pharmaceuticals, Inc. (RXRX) and Sana Biotechnology, Inc. (SANA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RXRX currently trades at $3.44 with a QOC of 6.5/10, while SANA trades at $3.13 with a QOC of 3.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).